Wolfe Highlights Differentiation Potential in Palisade Bio, Inc. (PALI) Clinical Profile [Yahoo! Finance]
Palisade Bio, Inc. (PALI)
Company Research
Source: Yahoo! Finance
TheFly reported on April 8 that Wolfe Research initiated coverage of PALI with an Outperform rating and a $7 price target. The firm expects limited near-term activity in 2026 but maintains a constructive long-term view. It points to upcoming ulcerative colitis data expected in the second half of 2027 as a key catalyst, noting that the company's mechanism and internal analyses support a positive outlook despite mixed results seen in similar drug classes. The firm's view is based on the potential for the program's clinical profile to differentiate over time as additional data become available. Earlier on March 30, Palisade Bio, Inc. (NASDAQ:PALI) reported early-stage results from its Phase 1b study of PALI-2108 in patients with fibrostenotic Crohn's disease. The oral PDE4 prodrug showed a favorable safety profile with no serious adverse events and only mild, self-limiting side effects. Pharmacokinetic findings supported once-daily dosing with adequate systemic and gut tissue exposure
Show less
Read more
Impact Snapshot
Event Time:
PALI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PALI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PALI alerts
High impacting Palisade Bio, Inc. news events
Weekly update
A roundup of the hottest topics
PALI
News
- Palisade Bio Announces Abstract Selected for Poster Presentation at Digestive Disease Week (DDW) 2026GlobeNewswire
- Palisade Bio (PALI) was upgraded by Wolfe Research to "strong-buy".MarketBeat
- Palisade Bio (PALI) is now covered by Wolfe Research. They set an "outperform" rating and a $7.00 price target on the stock.MarketBeat
- Palisade Bio to Present at the Needham & Co. 25th Annual Healthcare ConferenceGlobeNewswire
- Palisade Bio Shares Phase 1b PALI-2108 Data Showing Safety, PK and Early Crohn's Efficacy Signals [Yahoo! Finance]Yahoo! Finance
PALI
Sec Filings
- 4/17/26 - Form PRE
- 4/2/26 - Form 8-K
- 3/20/26 - Form 10-K
- PALI's page on the SEC website